{
  "id": "cad2e611b503d6bc",
  "title": "Saol Therapeutics Has Been Granted a Type A Meeting with the FDA to Determine the Path Forward for SL1009 in Pyruvate Dehydrogenase Complex Deficiency ( PDCD ) ",
  "description": "20251209T114500Z",
  "content": "",
  "source": "prnewswire.com",
  "source_url": "https://www.prnewswire.com/news-releases/saol-therapeutics-has-been-granted-a-type-a-meeting-with-the-fda-to-determine-the-path-forward-for-sl1009-in-pyruvate-dehydrogenase-complex-deficiency-pdcd-302635551.html",
  "published_at": "20251209T114500Z",
  "fetched_at": "2025-12-10T00:22:54.894572+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.prnewswire.com/news-releases/saol-therapeutics-has-been-granted-a-type-a-meeting-with-the-fda-to-determine-the-path-forward-for-sl1009-in-pyruvate-dehydrogenase-complex-deficiency-pdcd-302635551.html",
    "url_mobile": "",
    "title": "Saol Therapeutics Has Been Granted a Type A Meeting with the FDA to Determine the Path Forward for SL1009 in Pyruvate Dehydrogenase Complex Deficiency ( PDCD ) ",
    "seendate": "20251209T114500Z",
    "socialimage": "",
    "domain": "prnewswire.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}